## Dermatology Referral Form



## Fax completed form to:

PATIENT INFORMATION	
Patient Name: Date of Birth: Referral Date:	
Address: City/State/Zip:	
Home Phone:     Cell Phone:     Work Phone:	
Secondary Contact: Height: Weight: Male Female	
Patient Diagnosis & ICD-10:	
Allergies:	
PROVIDER INFORMATION	
Physician Name:     DEA #:	
Practice Name: NPI#:	
Address: City/State/Zip:	
Office Contact:     Phone:     Fax:       Supervisory Physician (if applicable):     Fax:     Fax:	
PLEASE ATTACH	
Patient demographics & front/back copy of all insurance cards (prescription & medical) TB lab results within last 12 months ( <i>Stelara, Simponi Aria, Ilumya &amp; Infliximabs only</i> UB/Lick and the state is the state of	//
Recent office visit notes, history & physical, lab & pertinent procedure results Current medication list & list of prior medications tried and failed (with dates) HBV lab results within last 12 months ( <i>Infliximabs &amp; Simponi Aria only</i> ) Letter of medical necessity if drug dosing or indication is outside of FDA guidelines	
NURSING & LAB ORDERS	
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion.	
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 100units/mL - 3-5mL flush after post-infusion NS flush if indicat	ed to maintain line
Lab Orders: Lab Date & Frequency:	
PRESCRIPTION ORDERS	
Anaphylaxis Kit:         Epinephrine 0.3mg IM as needed         Solu-cortef 250mg-500mg IV as needed         Solu-Medrol 60mg - 125mg IV as needed	
(Check all that apply) Diphenhydramine mg IV as needed NS Hydration 500 ml IV over 30 minutes as needed Other	
Pre-Medications:     Acetaminophenmg P0minutes prior to infusion     Solu-Medrolmg IVminutes prior to infusion	
(Check all that apply) Diphenhydramine mg POOR IV infusion minutes prior to infusion Other	
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary           PRODUCT         PRESCRIPTION INFORMATION	REFILLS
Is this a first dose? Yes No If No, when was last dose given?When is patient due for next dose?	KEFILLS
	1
ILUMYA 100mg SC injection at 0 and 4 weeks then every 12 weeks	
INFLIXIMAB Induction:mg/kg ormg IV infusion over at least 2 hours at weeks 0, 2, and 6	NONE
Avsola           Avsola         Maintenance:mg/kgmg IV infusion over at least 2 hours everyweeks	
Inflectra (Note: Round to nearest 100mg for Medicaid patients) Remicade	
Renflexis If Remicade infusion tolerated, adjust infusion time according to manufacturer package insert.	
SIMPONI ARIA 2 mg/kg IV infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter	
SPEVIGO 900 mg IV infusion over 90 minutes Additional 900 mg IV infusion over 90 minutes one week after initial dose if flare symptoms persist	
Psoriasis Adult Subcutaneous	
For patients <= 100 kg, 45 mg SC injection initially and 4 weeks later, followed by 45 mg every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks <b>Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)</b>	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks         Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks           Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)           STELARA         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks           For patients 60 kg – 100kg, 45 mg SC injection initially and 4 weeks later, then every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks         Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks         STELARA       Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks         STELARA       Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks	
STELARA         For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks           STELARA         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks           For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks           For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks           For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, then every 12 weeks           For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, then every 12 weeks           Psoriatic Arthritis Adult           45 mg SC injection initially and 4 weeks later, followed by 45 mg SC injection every 12 weeks           For patients with co-existent moderate-to-severe plaque psoriasis weighing >100 kg, 90 mg SC injection initially and 4 weeks           XOLAIR         150 or         300 mg SC injection once every 4 weeks	
For patients > 100 kg, 90 mg SC injection initially and 4 weeks later, followed by 90 mg every 12 weeks         STELARA       Psoriasis Pediatric Patients 6 to 17 (based on weight at time of initial dose)         For patients <= 60 kg, 0.75 mg/kg SC injection initially and 4 weeks later, then every 12 weeks	

Prescriber's Signature <u>Dispense as Written</u> Date

Prescriber's Signature Substitution Permitted Print Name

Date

